Israeli Cancer Research Firm Vaxil Granted 9th Patent for Immunotherapy TreatmentGlobeNewswire (press release)ISRAEL and TORONTO, May 03, 2018 (GLOBE NEWSWIRE) — VAXIL BIO LTD. (TSX VENTURE:VXL), a cancer research biotechnology company focused on inno… Continue reading
Israeli Cancer Research Firm Vaxil Granted 9th Patent for Immunotherapy TreatmentGlobeNewswire (press release)ISRAEL and TORONTO, May 03, 2018 (GLOBE NEWSWIRE) — VAXIL BIO LTD. (TSX VENTURE:VXL), a cancer research biotechnology company focused on inno… Continue reading
Israeli Cancer Research Firm Vaxil Granted 9th Patent for Immunotherapy TreatmentNasdaqISRAEL and TORONTO, May 03, 2018 (GLOBE NEWSWIRE) — VAXIL BIO LTD. (TSX VENTURE:VXL), a cancer research biotechnology company focused on innovative immunotherapy tr… Continue reading
The ColumnistInternational Synthetic Biology Market Research Report 2018Industry Today (press release)Global Synthetic Biology Market, provides a basic overview of the industry including definitions, classifications, applications and industry chain str… Continue reading
Tampa Bay Business Journal |
New HQ puts Tampa immunotherapy company in Moffitt’s backyard
Tampa Bay Business Journal Morphogenesis is developing targeted immunotherapies, or treatments that use the body’s own immune system to fight cancer. Many immunotherapies are personalized, or developed for each patient’s specific genetics, and can run into the hundreds of … |
Tampa Bay Business Journal |
New HQ puts Tampa immunotherapy company in Moffitt’s backyard
Tampa Bay Business Journal Morphogenesis is developing targeted immunotherapies, or treatments that use the body’s own immune system to fight cancer. Many immunotherapies are personalized, or developed for each patient’s specific genetics, and can run into the hundreds of … |
Drug Target Review |
T cell populations in CLL patients indicate potential success of CAR T cell therapy
Drug Target Review These healthier ‘early memory’ T cells were marked by the expression of CD8 and CD27, as well as the absence of CD45RO. The findings show the potential to improve responses by enhancing a patient’s immune cells with emerging cell manufacturing … |